Hologic, Inc. (HOLX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1155599,
    "name": "Hologic, Inc.",
    "stock_name": "Hologic, Inc.",
    "full_name": "Hologic, Inc.",
    "name_url": "stocks-analysis/hologic-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "74.86",
    "chg": 0.04,
    "chgp": "0.05%",
    "dir": 1,
    "prev_price": "74.82",
    "mcapval": "17,704.45",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US4364401012",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "7.26 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/hologic-inc-1155599-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Hologic, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hologic-inc-overvalued-or-undervalued-3637263",
        "imagepath": "",
        "date": "2025-10-21 11:58:50",
        "description": "As of 17 October 2025, the valuation grade for Hologic, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 21, an EV to EBITDA of 14.41, and a PEG ratio of 1.65. In comparison, Baxter International, Inc. has a higher P/E of 28.68, indicating a riskier valuation, while Align Technology, Inc. presents a more attractive P/E of 20.46.\n\nDespite Hologic's recent stock performance showing a 3.08% return over the past week compared to the S&P 500's 1.70%, the longer-term outlook reveals a decline with a -13.20% return over the past year versus the S&P 500's 14.08%. This suggests that while Hologic is currently fairly valued, its recent performance may raise concerns for investors...."
      },
      {
        "title": "Hologic, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/hologic-inc-sees-valuation-grade-change-from-expensive-to-fair-amid-price-increase-3640706",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/HologicInc_valuationdot_3640706.png",
        "date": "2025-10-20 16:13:49",
        "description": "Hologic, Inc. has recently adjusted its valuation, with a current P/E ratio of 21 and a Price to Book Value of 3.71. The company demonstrates solid profitability through metrics like a 17.31% ROCE and a 17.54% ROE, while its valuation metrics vary compared to peers in the sector."
      },
      {
        "title": "Is Hologic, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hologic-inc-overvalued-or-undervalued-3631671",
        "imagepath": "",
        "date": "2025-10-19 11:54:34",
        "description": "As of 17 October 2025, Hologic, Inc. has moved from an expensive to a fair valuation grade. The company appears fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 21, an EV to EBITDA of 14.41, and a PEG ratio of 1.65, which suggest that the stock is reasonably priced relative to its earnings growth potential.\n\nIn comparison to its peers, Hologic's P/E ratio of 21.83 is lower than Baxter International, Inc.'s risky valuation at 28.68 but higher than Align Technology, Inc.'s attractive valuation at 20.46. Additionally, Hologic's EV to EBITDA ratio is competitive within the industry, indicating a solid valuation position. Over the past year, Hologic's stock has underperformed against the S&P 500, returning -13.20% compared to the index's 14.08%, which may reflect market sentiment towards the stock despite its fair valuation...."
      },
      {
        "title": "Is Hologic, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hologic-inc-technically-bullish-or-bearish-3544867",
        "imagepath": "",
        "date": "2025-09-20 18:58:02",
        "description": "As of 29 August 2025, the technical trend for Hologic, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD remains bearish, indicating mixed signals across time frames. The weekly RSI shows no signal, but the monthly RSI is bullish, supporting the mildly bullish stance. Daily moving averages are bullish, and the weekly KST is also bullish, further reinforcing the positive outlook. However, the monthly KST and Bollinger Bands are bearish to mildly bearish, suggesting caution. Dow Theory indicates a mildly bullish trend on the monthly scale. \n\nIn terms of performance, Hologic has underperformed the S&P 500 year-to-date and over the past year, with returns of -5.30% and -16.46% respectively, compared to the S&P 500's 12.22% and 17.14%. Over three and five years, Hologic's returns are significantly lower than the S&P 500, with 2.17% and 7.39% compared to 70..."
      },
      {
        "title": "Is Hologic, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hologic-inc-overvalued-or-undervalued-3541595",
        "imagepath": "",
        "date": "2025-09-20 17:30:03",
        "description": "As of 5 February 2025, the valuation grade for Hologic, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 21, an EV to EBITDA of 14.41, and a PEG ratio of 1.65. In comparison, peers such as Align Technology, Inc. have a P/E ratio of 20.46 and an EV to EBITDA of 11.41, while Baxter International, Inc. shows a higher P/E of 28.68, suggesting that Hologic is positioned competitively within its industry.\n\nDespite its fair valuation, Hologic's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -5.30% compared to the S&P 500's 12.22%. Over the last year, Hologic has declined by 16.46%, while the S&P 500 has gained 17.14%, further emphasizing the challenges the company faces in the current market environment...."
      },
      {
        "title": "Hologic, Inc. Hits Day High with 7.69% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/hologic-inc-hits-day-high-with-769-surge-in-stock-price-3531633",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/HologicInc_priceRelatedfactors_3531633.png",
        "date": "2025-09-18 13:34:25",
        "description": "Hologic, Inc. has experienced a significant increase in stock performance, outperforming the S&P 500 in recent trading. Despite facing longer-term challenges, the company demonstrates strong management efficiency with a notable return on equity and low debt levels, indicating solid financial health in a competitive market."
      }
    ],
    "total": 11,
    "sid": "1155599",
    "stock_news_url": "https://www.marketsmojo.com/news/hologic-inc-1155599"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Hologic, Inc. overvalued or undervalued?

2025-10-21 11:58:50

As of 17 October 2025, the valuation grade for Hologic, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 21, an EV to EBITDA of 14.41, and a PEG ratio of 1.65. In comparison, Baxter International, Inc. has a higher P/E of 28.68, indicating a riskier valuation, while Align Technology, Inc. presents a more attractive P/E of 20.46. Despite Hologic's recent stock performance showing a 3.08% return over the past week compared to the S&P 500's 1.70%, the longer-term outlook reveals a decline with a -13.20% return over the past year versus the S&P 500's 14.08%. This suggests that while Hologic is currently fairly valued, its recent performance may raise concerns for investors....

Hologic, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape

2025-10-20 16:13:49

Hologic, Inc. has recently adjusted its valuation, with a current P/E ratio of 21 and a Price to Book Value of 3.71. The company demonstrates solid profitability through metrics like a 17.31% ROCE and a 17.54% ROE, while its valuation metrics vary compared to peers in the sector.

Is Hologic, Inc. overvalued or undervalued?

2025-10-19 11:54:34

As of 17 October 2025, Hologic, Inc. has moved from an expensive to a fair valuation grade. The company appears fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 21, an EV to EBITDA of 14.41, and a PEG ratio of 1.65, which suggest that the stock is reasonably priced relative to its earnings growth potential. In comparison to its peers, Hologic's P/E ratio of 21.83 is lower than Baxter International, Inc.'s risky valuation at 28.68 but higher than Align Technology, Inc.'s attractive valuation at 20.46. Additionally, Hologic's EV to EBITDA ratio is competitive within the industry, indicating a solid valuation position. Over the past year, Hologic's stock has underperformed against the S&P 500, returning -13.20% compared to the index's 14.08%, which may reflect market sentiment towards the stock despite its fair valuation....

Is Hologic, Inc. technically bullish or bearish?

2025-09-20 18:58:02

As of 29 August 2025, the technical trend for Hologic, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD remains bearish, indicating mixed signals across time frames. The weekly RSI shows no signal, but the monthly RSI is bullish, supporting the mildly bullish stance. Daily moving averages are bullish, and the weekly KST is also bullish, further reinforcing the positive outlook. However, the monthly KST and Bollinger Bands are bearish to mildly bearish, suggesting caution. Dow Theory indicates a mildly bullish trend on the monthly scale. In terms of performance, Hologic has underperformed the S&P 500 year-to-date and over the past year, with returns of -5.30% and -16.46% respectively, compared to the S&P 500's 12.22% and 17.14%. Over three and five years, Hologic's returns are significantly lower than the S&P 500, with 2.17% and 7.39% compared to 70...

Is Hologic, Inc. overvalued or undervalued?

2025-09-20 17:30:03

As of 5 February 2025, the valuation grade for Hologic, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 21, an EV to EBITDA of 14.41, and a PEG ratio of 1.65. In comparison, peers such as Align Technology, Inc. have a P/E ratio of 20.46 and an EV to EBITDA of 11.41, while Baxter International, Inc. shows a higher P/E of 28.68, suggesting that Hologic is positioned competitively within its industry. Despite its fair valuation, Hologic's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -5.30% compared to the S&P 500's 12.22%. Over the last year, Hologic has declined by 16.46%, while the S&P 500 has gained 17.14%, further emphasizing the challenges the company faces in the current market environment....

Hologic, Inc. Hits Day High with 7.69% Surge in Stock Price

2025-09-18 13:34:25

Hologic, Inc. has experienced a significant increase in stock performance, outperforming the S&P 500 in recent trading. Despite facing longer-term challenges, the company demonstrates strong management efficiency with a notable return on equity and low debt levels, indicating solid financial health in a competitive market.

View All News